What CMIC does

CMIC HOLDINGS Co., Ltd. (TYO:2309) is a Tokyo-headquartered, publicly listed pharmaceutical services group that pioneered Japan's Contract Research Organization (CRO) industry in 1992 and has grown to 7,761 employees across 27 group companies. The group provides an end-to-end services platform covering the full pharmaceutical value chain: consulting, non-clinical CRO (GLP safety studies, bioanalysis including LC-MS/MS and oligonucleotide analysis), clinical CRO (monitoring, data management, biostatistics, regulatory affairs, medical writing), CDMO (drug substance and product manufacturing with Japan Development Bank and Dainippon Printing partnerships), SMO (site management through a 2,600+ medical institution network), and CSO (commercial sales force). It also operates Orphan Pacific for rare-disease drug development and sales, including products such as Phebooky and Normosang.

CMIC generates revenue primarily through B2B professional services on a project/multi-year contract basis, supplemented by licensing/royalty income from orphan drugs and recurring consumer revenue from digital health platforms. Core technology assets include the harmo electronic medication record platform, the animo One Health platform for animal healthcare (integrated with Anicom's veterinary claims cloud), proprietary Risk-Based Monitoring (RBM) methodology, and an agentic AI deployment (via Bluenote partnership) for clinical development documentation. Consumer-facing products (SelCheck HPV self-screening, HelC Online Shop, harmo vaccine care) are sold direct-to-consumer, through pharmacy networks, and via corporate/health-insurance wellness programs.

The customer base is anchored by domestic Japanese pharmaceutical companies and overseas pharma entering Japan through the Innovative Pharma Model (IPM) framework, with named enterprise relationships including Boehringer Ingelheim Animal Health Japan and Celltrion Healthcare Japan. In March 2025, Blackstone acquired a 60% majority stake in the operating CRO (CMIC Co., Ltd.), with CMIC HOLDINGS retaining 40%, marking a shift toward private-equity-backed expansion and technology investment. The group also divested its US bioanalytical subsidiary (CMIC, INC., Chicago) to SGS in June 2026, refocusing on Japan-anchored operations and Asia-Pacific partnerships.

Name

CMIC

Legal name

CMIC HOLDINGS Co., Ltd.

Website

https://www.cmicgroup.com/

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

CMIC HOLDINGS (TYO:2309) is Japan's pioneering end-to-end pharmaceutical services group, offering consulting, non-clinical and clinical CRO, CDMO, SMO, and CSO services to pharma, biotech, and overseas companies entering Japan, with digital health platforms harmo and animo.

Ownership category

akta.pro rank

Product category

Pharmaceutical CRO Services

NAICS

Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)

akta.pro primary industry

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

akta.pro secondary industries

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL), Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical CRO services
• Clinical research organization
• CDMO manufacturing services
• Drug development solutions
• Digital health platforms

Headquarters

HQ city

Shibaura

HQ country

Japan

HQ region

Asia

Offices16 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. CRO Services (Clinical Research Organization): Core clinical development services including clinical trial monitoring (CRA), data management, biostatistics, regulatory affairs, and medical writing. CMIC provides full-service CRO capabilities across all phases and therapeutic areas, serving both Japanese and international pharmaceutical companies.
2. Non-Clinical CRO: Pre-clinical testing services including safety assessment, pharmacokinetics, bioanalysis (LC-MS/MS, immunoassay, oligonucleotide analysis), imaging support, and non-GLP exploratory studies. Operates GLP-compliant facilities serving global regulatory submissions.
3. CDMO (Contract Development and Manufacturing Organization): Pharmaceutical product development and manufacturing services including drug substance and drug product manufacturing, with partnerships with Japan Development Bank and Dainippon Printing for expanded manufacturing capacity.
4. SMO Services (Site Management Organization): Site management and CRC (Clinical Research Coordinator) services across a network of more than 2,600 medical institutions in Japan, supporting efficient clinical trial site operations.
5. CSO Services (Contract Sales Organization): Pharmaceutical sales and marketing services in Japan, providing sales force augmentation for pharmaceutical companies.
6. Orphan Drug / Specialty Pharma (Orphan Pacific): Development and sales of orphan drugs (rare disease pharmaceuticals) through subsidiary Orphan Pacific Co., Ltd., including products such as Phebooky® (for urea cycle disorders) and Normosang® (for acute porphyria).
7. Digital Health / Healthcare Solutions: Healthcare platform services including harmo electronic medication records, SelCheck self-testing kits, HelC health portal, and other digital health solutions for consumers, corporations, and health insurance associations.
8. Animal Healthcare (animo): One Health platform services for veterinary healthcare including animo platform, IKIGAI Pet Centers, veterinary hospital operations, and data services supporting animal drug development.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels8 records

Core offering

CMIC provides end-to-end pharmaceutical development and commercialization services through its CRO (clinical and non-clinical), CDMO (contract development and manufacturing), SMO (site management), and CSO (contract sales) business lines. The company also operates digital health platforms (harmo electronic medication records, SelCheck self-testing kits), animal healthcare platforms (animo), and develops/sells orphan drugs through subsidiary Orphan Pacific, covering the full pharmaceutical value chain from non-clinical studies through post-marketing commercialization.

Product overview

CMIC Holdings is a comprehensive pharmaceutical and healthcare solutions group operating across three core solution areas: Pharmaceutical Solutions (covering the full drug development value chain — consulting, non-clinical CRO, clinical CRO, CDMO, SMO, and CSO), Healthcare Solutions (digital health platforms, personal health management, and local government support), and Specialized Solutions (tailored offerings for patients and medical institutions). The group also operates an animal health subsidiary (animo) offering pet health management platforms (animo owner app, animo for VET) and a pet healthcare center. Key platforms include harmo (electronic medication notebook), CMIC's RBM (risk-based monitoring for clinical trials), SelCheck (cervical cancer screening), and LobSense (heat stress sensing). The portfolio is unified by CMIC's 'End-to-End' strategy — supporting drug development from discovery through post-marketing, and extending into personal and animal health — under the group mission of contributing to healthcare innovation so that everyone can live a healthier life.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Solutions (Pharma Solutions) Comprehensive end-to-end support for pharmaceutical companies covering consulting, non-clinical CRO, clinical CRO, CDMO, SMO, and CSO services, spanning the full value chain from preclinical development through manufacturing and post-marketing. Targeted at domestic Japanese and global pharmaceutical companies.
• Healthcare Solutions Digital health platforms and local government support solutions that create new value in healthcare, including personal health management, vaccination support, and community health services.
• Specialized Solutions Tailored solutions for patients, medical institutions, and healthcare providers addressing specific needs across the healthcare ecosystem in Japan.
• harmo Electronic Medication Record Platform Digital health platform enabling patients to manage and share medication information with healthcare providers, supporting medication error checking, vaccine record management (harmo vaccine care), and integration with healthcare systems.
• animo Platform (Animal Healthcare) One Health platform connecting animal and human healthcare, featuring animo owner app and animo for VET. Collects real-world data (RWD) from daily veterinary clinical practice to support evidence generation for animal drug development.
• SelCheck Self-Testing Kits HPV self-sampling kit for cervical cancer screening enabling women to collect samples at home with results reviewed by physicians, available through corporate health programs and direct-to-consumer online sales.
• CMIC's RBM (Risk-Based Monitoring) Risk-based monitoring approach for clinical trial oversight that focuses on problem prevention rather than problem detection, enabling more efficient and effective clinical trial oversight across multiple therapeutic areas.
• Kobuchizawa IKIGAI Pet Center Comprehensive pet healthcare facility in Yamanashi Prefecture offering veterinary services, nursing care, pet hotel, and grooming services tailored to pet life stages.
• Orphan Drug Products (Orphan Pacific) Development and sales of orphan drugs (rare disease pharmaceuticals) through subsidiary Orphan Pacific Co., Ltd., including products such as Bufenil/Phebooky (for urea cycle disorders), Normosang (for acute porphyria), and Ravicti (urea cycle disorder treatment).
• LobSense Heat Stress Sensor Ear-lobe surface temperature sensing technology for measuring heat stress in industrial workers, developed jointly with ENEOS Corporation with deployment at refineries for safety monitoring.

Quantifiable outcome

• Up to 75% reduction in clinical documentation timelines through Bluenote agentic AI deployment
• +2 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered flagship, minor and core.

• SGSflagshipStrategic or Co-development Partner · 3 June 2026SGS, the world's leading testing, inspection and certification company, acquired CMIC, INC. (Chicago-based bioanalytical testing subsidiary). CMIC HOLDINGS and SGS will continue collaboration through CMIC Pharma Science Co., Ltd. which operates analytical laboratories in Japan. The deal supports SGS's Strategy 27 objective to double North American sales between 2023 and 2027.
• Japan Digital Health Alliance (JaDHA) / AI Safety Institute (AISI)minorStrategic or Co-development Partner · 3 April 2026CMIC participated as a core member (幹事企業) in the Japan Digital Health Alliance's collaboration with the AI Safety Institute to develop the Healthcare AI Safety Evaluation Guide for large language models and generative AI in healthcare. CMIC contributed to drafting and reviewing guideline sections.
• Celltrion Healthcare JapancoreStrategic or Co-development Partner · 17 March 2026Celltrion Healthcare Japan and CMIC Group signed a comprehensive business partnership (MOU) to jointly expand Celltrion's biosimilar business in the Japanese market. Partnership combines Celltrion's global biosimilar R&D and product portfolio with CMIC's end-to-end pharmaceutical value chain support spanning development, manufacturing, and sales in Japan. Aims to address Japan's policy goal of achieving over 80% biosimilar penetration by end of FY2029.
• BluenotecoreTechnology or Integration · 10 March 2026CMIC Co., Ltd. (jointly owned by Blackstone and CMIC HOLDINGS) partnered with Bluenote to deploy agentic AI across clinical development workflows. Collaboration covers protocol development, statistical analysis planning, and study report production, with claims of up to 75% acceleration in documentation processes. Platform designed to align with ICH, FDA, PMDA, and EMA regulatory standards. Aligned with Blackstone's strategy since acquiring 60% interest in CMIC.
• Okeios Co., Ltd.minorStrategic or Co-development Partner · 15 November 2023CMIC Solutions Co., Ltd. acquired additional shares of Okeios Co., Ltd. to strengthen business in medical and healthcare technology. Aimed at expanding support for personal health management and integrating fragmented health information using blockchain technology.
• Hamamatsu Pharma Research Co., Ltd. (株式会社浜松ファーマリサーチ)coreStrategic or Co-development Partner · 1 October 2023CMIC Holdings acquired Hamamatsu Pharma Research as a subsidiary in October 2023 to enhance pharmaceutical development support. Combines CMIC's CRO capabilities with Hamamatsu Pharma Research's expertise in non-clinical trials, expanding market reach and strengthening global pharmaceutical value chain.
• Knock on the Door Co., Ltd. (ノックオンザドア)coreStrategic or Co-development Partner · 19 October 2022CMIC Holdings acquired majority stake in Knock on the Door Co., Ltd., making it a subsidiary. Company operates nanacara pharmacy chain, enhancing digital health platforms and fostering collaborations with medical institutions. nanacara pharmacy won Special Jury Prize at 8th Pharmacy Awards (2024).
• Kyoto University / Town of Rankoshi, HokkaidominorStrategic or Co-development Partner · 1 March 2020CMIC HOLDINGS entered joint research agreement with Kyoto University and the town of Rankoshi to promote regional revitalization through cultivation of medicinal plants (ginseng, senna, perilla) as raw materials for Kampo/herbal medicines. Includes YouTube channel for project outreach.
• Anicom HoldingscoreStrategic or Co-development Partneranimo (CMIC Group) partnered with Anicom to develop PHR-EMR systems for veterinary healthcare. Partnership combines animo's platform data (2,600+ facilities, 10M animal records) with Anicom's claims data to create B2B real-world data services for animal health. Connected with Anicom's veterinary hospital cloud system.
• Toyooka City Medical Association (新城市医師会)minorOthersCollaboration with Toyooka City Medical Association for animal healthcare evidence generation surveys using the animo platform, coordinated through Dr. Shirai's veterinary clinic.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• ICON plc: Major global CRO offering clinical research, consulting, and laboratory services post-PRA Health Sciences merger. Directly competes with CMIC for multi-region clinical trial business and shares the integrated CRO/CDMO model.
• Shin Nippon Biomedical Laboratories (SNBL): Japan's leading non-clinical CRO specializing in translational research and safety pharmacology. Closely comparable to CMIC's non-clinical CRO and Hamamatsu Pharma Research operations acquired in 2023.
• Syneos Health: Fully integrated biopharmaceutical solutions organization combining clinical CRO with commercial (CSO) services. Highly comparable business model to CMIC's integrated CRO+CSO value chain.
• IQVIA Holdings: World's largest CRO with comprehensive clinical, technology, and consulting services across all major markets. Directly comparable to CMIC as a full-service CRO competing for global pharma trials, though with significantly larger scale and broader geographic footprint.
• EPS Holdings: Japan-based CRO and SMO operating full-service clinical research and site management across Asia. The most direct domestic Japanese competitor to CMIC's clinical CRO and SMO operations.
• Medpace Holdings: Full-service clinical CRO focused on small-to-mid sized biopharma sponsors. Comparable to CMIC as a clinical CRO competitor, particularly for smaller and mid-sized pharma trials in Asia-Pacific.
• Charles River Laboratories: Major non-clinical CRO/CDMO with strong preclinical, safety assessment, and biopharmaceutical manufacturing capabilities. Closely parallels CMIC's non-clinical CRO and CDMO services, including biologics manufacturing through CMIC BIO.
• Fortrea Holdings: Spun off from Labcorp in 2023 as a dedicated clinical CRO offering clinical trial management, bioanalysis, and central lab services. Closely comparable to CMIC's clinical CRO and bioanalytical offerings (note: SGS acquired CMIC's bioanalytical operations).
• PAREXEL International: Global CRO (private since EQT/Goldman take-private in 2021) providing clinical development, regulatory consulting, and commercialization services. Comparable to CMIC's full-service offering and Japan market access capabilities.

Regional players

• InCROM (formerly CMIC Holdings competitor): Japanese SMO/CRO providing clinical trial site management and clinical research services. Comparable to CMIC's SMO operations and regional Japanese trial execution capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/CMIC_Group
• YouTubeyoutube.com/channel/UCvcNZ3lQxYbzWzVeqRKKoJQ
• LinkedInlinkedin.com/company/cmic-group/?viewAsMember=true
• Instagraminstagram.com/ikigai_petcenter

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CMIC